New study tracks xarelto safety in infants with blood clots

NCT ID NCT05900388

Not yet recruiting Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This observational study will collect data from health records of 850 children under 2 years old who have venous thromboembolism (blood clots). The goal is to see how doctors prescribe rivaroxaban (Xarelto) and other standard blood thinners, and to track any serious bleeding. No new treatments or tests are given—researchers simply analyze existing information from national health databases in Denmark, Sweden, France, and Spain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Rivaroxaban (Xarelto) oral suspension
What this could lead to
If successful, this study could provide better information on how rivaroxaban is used and how safe it is in very young children with blood clots.
What could go wrong
This is an observational study that only looks at existing data, so it cannot prove cause and effect. Results may be limited by the quality of the records and may not apply to all children.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHILDREN UNDER 2 YEARS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Many locations

    Multiple Locations, Denmark

  • Many locations

    Multiple Locations, France

  • Many locations

    Multiple Locations, Spain

  • Many locations

    Multiple Locations, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.